Spivak JL - Search Results

1

Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease.

Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, Dang CV, Brodsky I, Jones RJ. Brodsky RA, et al. Among authors: spivak jl. Ann Intern Med. 1998 Dec 15;129(12):1031-5. doi: 10.7326/0003-4819-129-12-199812150-00007. Ann Intern Med. 1998. PMID: 9867758 Clinical Trial.

2

Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.

Rowinsky EK, Conley BA, Jones RJ, Spivak JL, Auerbach M, Donehower RC. Rowinsky EK, et al. Among authors: spivak jl. Leukemia. 1992 Jun;6(6):526-34. Leukemia. 1992. PMID: 1602791

3

The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns.

Streiff MB, Smith B, Spivak JL. Streiff MB, et al. Among authors: spivak jl. Blood. 2002 Feb 15;99(4):1144-9. doi: 10.1182/blood.v99.4.1144. Blood. 2002. PMID: 11830459 Free article.

4

Decreased erythropoietin response in patients with the anemia of cancer.

Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Miller CB, et al. Among authors: spivak jl. N Engl J Med. 1990 Jun 14;322(24):1689-92. doi: 10.1056/NEJM199006143222401. N Engl J Med. 1990. PMID: 2342534 Free article.

5

Impaired erythropoietin response to anemia after bone marrow transplantation.

Miller CB, Jones RJ, Zahurak ML, Piantadosi S, Burns WH, Santos GW, Spivak JL. Miller CB, et al. Among authors: spivak jl. Blood. 1992 Nov 15;80(10):2677-82. Blood. 1992. PMID: 1421381 Free article.

6

Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.

Rowinsky EK, Donehower RC, Spivak JL, Burke PJ, Griffin CA, Jones RJ. Rowinsky EK, et al. Among authors: spivak jl. J Natl Cancer Inst. 1990 Dec 19;82(24):1926-31. doi: 10.1093/jnci/82.24.1926. J Natl Cancer Inst. 1990. PMID: 2250314

7

Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells.

Ye Z, Liu CF, Lanikova L, Dowey SN, He C, Huang X, Brodsky RA, Spivak JL, Prchal JT, Cheng L. Ye Z, et al. Among authors: spivak jl. Stem Cells. 2014 Jan;32(1):269-78. doi: 10.1002/stem.1545. Stem Cells. 2014. PMID: 24105986 Free PMC article.

8

Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders.

Ye Z, Zhan H, Mali P, Dowey S, Williams DM, Jang YY, Dang CV, Spivak JL, Moliterno AR, Cheng L. Ye Z, et al. Among authors: spivak jl. Blood. 2009 Dec 24;114(27):5473-80. doi: 10.1182/blood-2009-04-217406. Epub 2009 Oct 1. Blood. 2009. PMID: 19797525 Free PMC article.

9

Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.

Spivak JL. Spivak JL. Ann Intern Med. 2010 Mar 2;152(5):300-6. doi: 10.7326/0003-4819-152-5-201003020-00008. Ann Intern Med. 2010. PMID: 20194236 Review.

10

Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.

Watson AJ, Gimenez LF, Cotton S, Walser M, Spivak JL. Watson AJ, et al. Among authors: spivak jl. Am J Med. 1990 Oct;89(4):432-5. doi: 10.1016/0002-9343(90)90371-j. Am J Med. 1990. PMID: 2220877 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters